In conclusion, our study highlights the role of DOCK1 in determining the response of liver cancer cells to metformin treatment and illustrates the inhibition of tumor progression by metformin in liver cancer patients with low DOCK1 expression. This evidence concerns the gene DOCK1 and neoplasm.